États-Unis · Bourse & Finance · Morningstar

Nanoscope Therapeutics to Participate in Eyecelerator 2026 and the American Academy of Ophthalmology 2026 Annual Meeting

Publié par Morningstar · États-Unis il y a 16 h

Four-year REMAIN data from the RESTORE Phase 2b/3 trial of MCO-010 in retinitis pigmentosa and a scientific poster on dry AMD to be presented at the AAO 2026 Annual Meeting,…

Lire l'article complet sur Morningstar Connectez-vous pour sauvegarder

MediaNews présente le titre et le résumé publiés par le média. L'article complet se lit sur le site de l'éditeur. (www.morningstar.com)

Nanoscope Therapeutics to Participate in Eyecelerator 2026 and the American Academy of Ophthalmology 2026 Annual Meeting

À lire aussi

UBS to shed fund administration business acquired through Credit Suisse merger

Trump allows cheaper, dyed diesel on highways to blunt historic fuel-cost spike ahead of midterms

True Food Kitchen filed for bankruptcy and closed 12 restaurants

Japan Courts Saudi Arabia and UAE as Asia's Oil Supply Fears Persist

The VIX of bonds is rising but bitcoin and stocks aren't hearing it yet

Best Oil Stocks Right Now

Nanoscope Therapeutics to Participate in Eyecelerator 2026 and the American Academy of Ophthalmology 2026 Annual Meeting

Partager

À lire aussi

UBS to shed fund administration business acquired through Credit Suisse merger

Trump allows cheaper, dyed diesel on highways to blunt historic fuel-cost spike ahead of midterms

True Food Kitchen filed for bankruptcy and closed 12 restaurants

Japan Courts Saudi Arabia and UAE as Asia's Oil Supply Fears Persist

The VIX of bonds is rising but bitcoin and stocks aren't hearing it yet

Best Oil Stocks Right Now